Heart Failure

Compared with later initiation, starting sacubitril/valsartan within 3 months of a diagnosis of HF with reduced ejection fraction was tied to better clinical outcomes and earlier left ventricular reverse remodeling, researchers reported.

Cardiac MRI demonstrated superiority to transthoracic echocardiography in identifying elevated left ventricular filling pressure among patients with suspected HF presenting with breathlessness, researchers reported.

The FDA approved magnetic resonance conditional labeling for an implantable neurostimulator HF device, allowing patients with the device to safely undergo MRI, according to a press release from CVRx.

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.

Tissue regeneration has been achieved in certain parts of the body, but not the heart. That could change if a novel therapeutic derived from messenger RNA succeeds.

Strados Labs announced it received FDA clearance for home use of its smart sensor platform for respiratory health, according to a press release.

Impulse Dynamics announced it received FDA and CE Mark approval and launched its miniature next-generation cardiac contractility modulation therapy delivery system.

In this video, Lynne Warner Stevenson, MD, discusses new guidelines regarding the use of SGLT2 inhibitors from the American College of Cardiology Scientific Session

In this video, Lynne Warner Stevenson, MD, professor of medicine at Vanderbilt University Medical Center, discusses new HF developments stemming from the American College of Cardiology Scientific Session

Fenofibrate was associated with a reduction in heart failure hospitalizations and cardiovascular-related mortality compared with placebo in patients with type 2 diabetes who received simvastatin, according to recent data.